Category Archives: News Releases

SAN LUIS OBISPO, California, October 15, 2024 — FzioMed, Inc. (“FzioMed” or the “Company”), a recognized global leader in post-surgical adhesion prevention, today announced it will attend the European Society of Gynecological Endoscopy (ESGE) 33rd annual congress October 27-30 in Marseille, France. The Company will showcase its innovative Oxiplex/IUâ and Oxiplex/APâ adhesion barrier gels designed …

SAN LUIS OBISPO, California, October 1, 2024 — FzioMed, Inc. (“FzioMed” or the “Company”), a recognized global leader in post-surgical adhesion prevention, today announced it was recently named one of the 2024 Best Places to Work in Southern California. This is the second consecutive year the Company has been recognized by the annual program organized …

SAN LUIS OBISPO, California, June 17, 2024 — FzioMed, Inc. (“FzioMed” or the “Company”), a recognized global leader in post-surgical adhesion prevention, today announced it will attend the Federation of European Societies for the Surgery of the Hand (FESSH) congress June 26-29 in Rotterdam, The Netherlands. The Company will showcase its innovative Dynavisc® adhesion barrier …

SAN LUIS OBISPO, California, April 16, 2024 — FzioMed, Inc. (“FzioMed” or the “Company”), a recognized global leader in adhesion prevention, today announced it will attend the Hysteroscopy, Assisted Reproductive Technology and Ultrasound (HARTUS) congress April 22-24 in Rome, Italy. The Company will showcase its innovative Oxiplex® adhesion barrier gel product portfolio designed to reduce …

Company sets refreshed global strategy and new US initiatives for Oxiplex® portfolio of adhesion barrier products in women's health, spine, orthopedics and general surgery. SAN LUIS OBISPO, Calif., May 17, 2023  -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine, orthopedic, peritoneal and gynecological surgery, today announced the appointment of …

New CEO Paul Mraz also joins FzioMed Inc.’s Board of Directors; Company set to accelerate growth of market leading Oxiplex® adhesion barrier products. SAN LUIS OBISPO, California, January 3, 2023 — FzioMed, Inc. (“FzioMed” or the “Company”), a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, today announced the appointment of …

San Luis Obispo, California – FzioMed, Inc., a leading biomaterials company, is pleased to announce that Oxiplex shipments have now passed the 600,000 unit mark. Oxiplex is approved outside the United States in more than 70 countries and distributed under various brand names including Oxiplex, Oxiplex/SP, MediShield and Interpose. Oxiplex is an absorbable gel applied …

SAN LUIS OBISPO, Calif., March 28, 2019 - Oxiplex® is an absorbable, synthetic viscoelastic gel that is applied following partial discectomy, with the intent to reduce postoperative leg pain, back pain and neurologic symptoms. Oxiplex® is approved in more than 70 countries as an adhesion barrier, supported by peer reviewed, published studies. More information on …

SAN LUIS OBISPO, Calif., Oct. 3, 2018 - Oxiplex/IU® is CE marked and available in the European Union. It is an absorbable, synthetic viscoelastic gel that is applied following intrauterine surgery to preserve uterine integrity and improve surgical outcomes by reducing post-surgical adhesions. Learn more at www.fziomed.com, or find us on LinkedIn: www.linkedin.com/company/fziomed-inc. "We have been …

FzioMed is pleased to announce the enrollment of patient number one in the supportive study of Oxiplex® in patients undergoing lumbar surgery for disc herniation SAN LUIS OBISPO, Calif., July 23, 2018 -- Oxiplex® is an absorbable, synthetic viscoelastic gel that is applied following partial discectomy, with the intent to reduce postoperative leg pain, back pain and …

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--FzioMed, Inc. a leading biomaterials company, is pleased to announce that Oxiplex sales have now passed the 500,000 unit mark. Oxiplex is approved outside the United States in more than 70 countries and distributed under various brand names; including, Oxiplex, Oxiplex/SP, MediShield, and Interpose. Oxiplex is an absorbable gel applied to …

Confirmatory Clinical Study to Support the Effectiveness and Safety of Oxiplex® for the Reduction of Pain and Symptoms Following Lumbar Surgery. SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--FzioMed, Inc., a biomaterials company celebrating 21 years in business, has received approval from FDA to conduct a small confirmatory study of Oxiplex® in the United States. Oxiplex® is an …

COMPOSITIONS OF CARBOXYMETHYLCELLULOSE AND POLYETHYLENE OXIDE IONICALLY CROSS-LINKED USING POLYHYDROXYL ORGANIC ANIONS. San Luis Obispo, California, May 2, 2017. FzioMed, which celebrates 21 years in business this year has received a new  patent, US 9,636,434. Methods for manufacturing ionically cross-linked compositions of carboxypolysaccharides, polyalkylene oxides,polyhydroxyl organic anions, optionally divalent cations and aqueous media are also …

SAN LUIS OBISPO, California, November 2nd 2015. FzioMed, Inc., which recently celebrated 19 years in the medical device business, has received a new patent, US 9,161,987 B2, for crosslinked compositions of carboxymethylcellulose (CMC) and polyethylene glycol (PEG) for medical uses.  The crosslinking technology provides devices that can be made with a variety of viscoelastic properties, to …

SAN LUIS OBISPO, California – July 7th, 2015 - FzioMed, Inc. (www.fziomed.com) announced that it has shipped the 400,000th unit of Oxiplex® gel.  Oxiplex is approved outside the United States in 70 countries and is distributed under the brand names Oxiplex®, Oxiplex®/SP and MediShield™. Oxiplex is an absorbable gel that is applied to spinal nerve …

SAN LUIS OBISPO, California—July 21st, 2014—FzioMed, Inc., a manufacturer and marketer of synthetic biomaterials is pleased to announce the issuance of a new patent in Europe, ‘Chemically Activated Carboxypolysaccharides and Uses’. This invention relates to derivatized carboxypolysaccharides (CPS) and their uses in gels and films incorporating polyethylene oxide (PEO) for drug delivery, and for hemostatic …

SAN LUIS OBISPO, California—May 28th, 2014— FzioMed, Inc. today announced it has agreed with the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) to postpone the Dispute Resolution Panel for its Oxiplex PMA; the meeting was previously scheduled for June 10.  The postponement was agreed between the parties …

Already approved in 70 Countries, Medical Device Dispute Resolution Panel will Weigh Whether Oxiplex Should Also be Made Available in the U.S. SAN LUIS OBISPO, California—April 11th, 2014—FzioMed, Inc., a medical device manufacturer specializing in biomaterials, has received notification from FDA that the Medical Device Dispute Resolution Panel (MDDRP) will convene and make a decision …

Approved in 70 Countries, Panel will Weigh Whether Oxiplex Should Also be Available in the U.S. SAN LUIS OBISPO, California—November 4th, 2013—FzioMed, a medical device company that recently celebrated the 17th anniversary of its founding, has received approval from the Commissioner of the U. S. Food and Drug Administration of its Petition for an independent …

SAN LUIS OBISPO, California – May 6th 2013 - FzioMed, a privately held medical device company based in San Luis Obispo, CA., is pleased to announce the inclusion of Dynavisc on the Australian Register of Therapeutic Goods (ARTG). Dynavisc is an absorbable, clear, viscoelastic gel that is applied to tendons and peripheral nerves to reduce …

Download

SAN LUIS OBISPO, California – January 22nd 2013 - FzioMed, a privately held medical device company based in San Luis Obispo, CA., is pleased to announce the approval of Oxiplex in Russia. Oxiplex is an absorbable, clear, viscoelastic gel that is applied during lumbar spine surgery immediately prior to wound closure.  Based on four studies …

SAN LUIS OBISPO, California – December 3, 2012 - FzioMed, a privately held medical device company based in San Luis Obispo, CA, has filed a petition for reconsideration with the U.S. Food and Drug Administration, under Section 515(g)(2)(a) of the Food Drug Cosmetic Act, Section 562 of the FD&C act and Part 10.33 of Title …

SAN LUIS OBISPO, California – September 24, 2012   – FzioMed, Inc. (www.fziomed.com) announced that they have shipped the 300,000th unit of Oxiplex®. Oxiplex is approved outside of the United States in 68 countries worldwide and is distributed under the brand names Oxiplex®, Oxiplex®/SP and MediShield™. Oxiplex is an absorbable gel that is applied to spinal nerve …

Oxiplex Reduces Leg Pain, Back Pain and Associated Symptoms Following Lumbar Discectomy. SAN LUIS OBISPO, California – April 15th, 2012 - FzioMed, Inc. today announced the publication of results from the Oxiplex® pivotal clinical study in today’s issue of Spine, the leading international peer-review journal for study of the spine. Oxiplex is an absorbable gel …

New Adhesion Barrier Gel for Tendon and Peripheral Nerve Surgery SAN LUIS OBISPO, California – January 23, 2012 - FzioMed, Inc. is pleased to announce that it has received CE Mark approval to market DYNAVISC® adhesion barrier gel in Europe for tendon and peripheral nerve surgery. DYNAVISC is a clear, absorbable gel supplied ready-to-use in …

SAN LUIS OBISPO, California – November 1, 2011 – FzioMed, Inc. (www.fziomed.com) announced that they have reached the 250,000 units sold mark. Oxiplex® is approved outside of the United States in over 70 countries worldwide under the brand names Oxiplex®, Oxiplex®/SP and MediShield™. Oxiplex is an absorbable gel that is applied to spinal nerve roots during …

SAN LUIS OBISPO, California – April 28, 2011 – FzioMed, Inc. announced today the launch of www.fziomed.com that has been transformed into an interactive tool to enhance the online experience of Healthcare Professionals, Distributors and Consumers searching for healthcare information.   The primary objective when designing the website was to provide an effective medium that would showcase the growing …

SAN LUIS OBISPO, California - November 29, 2010 - FzioMed, Inc. announced a major milestone in sales as the 200,000th unit of Oxiplex left its California manufacturing facility. Outside the U.S., Oxiplex also known as MediShield, is approved for sale in 63 countries including Canada, Australia, South Korea, Brazil and the entire European Union. "Over …

SAN LUIS OBISPO, California - November 2, 2010 - FzioMed, Inc. announced today that it was awarded cash grants totaling approximately $244,479 under the US Government's Therapeutic Discovery Project (QTDP) program. "We are delighted to receive this grant for our clinical program addressing unmet medical needs in the field of adhesion prevention," said John S. …

SAN LUIS OBISPO, California - May 19, 2010 - FzioMed, Inc. announced today the publication of Use of Temporary Implantable Biomaterials to Reduce Leg Pain and Back Pain in Patients with Sciatica and Lumbar Disc Herniation. The peer-review article was published on mdpi.com (Special Issue Advances in Biomaterials, Received: 23 January 2010; in revised form: …

SAN LUIS OBISPO, California - March 30, 2010 - FzioMed, Inc. announced today expansion of Oxiplex® Adhesion Barrier Gel for Spine Surgery in both Asia and South America. In late 2009, FzioMed obtained approval for the Oxiplex® brand in South Korea and Brazil, and the Company recently appointed additional distributors in both countries. Product training …

SAN LUIS OBISPO, California - July 17, 2008 - FzioMed, Inc. today said that it strongly disagrees with the recommendation made July 15 by the U.S. Food and Drug Administration (FDA) Orthopaedic and Rehabilitation Devices Advisory Panel, that the Company's Premarket Approval (PMA) application for Oxiplex gel was not approvable. The advisory panel's action constitutes …

SAN LUIS OBISPO, California - February 29, 2008 - FzioMed, Inc. today announced that Health Canada has approved the company's Oxiplex® gel for use in lumbar spine surgery. Oxiplex is an absorbable gel that is applied to spinal nerve roots during lumbar laminectomy, laminotomy and discectomy procedures. Oxiplex creates a temporary, protective barrier against the …

FzioMed Appoints Todd Fanning as Vice President of Sales SAN LUIS OBISPO, California - November 5, 2007 - FzioMed, Inc., a leader in surgical biomaterials, announced today the appointment of Todd P. Fanning to the position of Vice President of Sales. Mr. Fanning is a seasoned sales executive with over twenty years of experience growing …

Oxiplex Targets Unmet Need; Application to Receive Expedited Processing SAN LUIS OBISPO, California - October 4, 2007 - FzioMed, Inc. announced today that the U.S. Food and Drug Administration (FDA) has completed its initial review of the company's Pre-Market Approval (PMA) application for Oxiplex spine surgery gel and has accepted the PMA for filing. FDA …

SAN LUIS OBISPO, California - August 1, 2007 - FzioMed, Inc., a leader in surgical biomaterials, announced today the appointment of Kevin K. Sidow, former St. Francis Medical Technologies, Inc. President and CEO, to FzioMed's board of directors. While at St. Francis Medical, Mr. Sidow was responsible for overall operations and the achievement of milestones …

SAN LUIS OBISPO, California - June 15, 2007 - FzioMed, Inc., a leader in surgical biomaterials, announced today the appointment of James R. Peters to the Company's board of directors. "Jim brings a wealth of knowledge and experience in the successful leadership of growing companies such as FzioMed," said Ron Haynes, Chairman of FzioMed, Inc. …

SAN LUIS OBISPO, California - November 16, 2006 - FzioMed, Inc. reported today that a review of the company’s technology for postsurgical adhesion prevention has been published in The Journal of Biomedical Material Research, Wiley Periodicals, Inc. The article, "A Modern Biomaterial for Adhesion Prevention" (J Biomed Mater Res Part B: Appl Biomater, 2006 DOI …

SAN LUIS OBISPO, California - October 13, 2006 - FzioMed, Inc. announced today reports of positive clinical experiences by European surgeons using the company’s adhesion barrier gel to prevent postoperative adhesions from forming after back surgery. Presentations are being made at annual meetings of the Congress of Neurological Surgeons (CNS) in Chicago this week and …

SAN LUIS OBISPO, California – May 9, 2006 – FzioMed, Inc. announced today the presentation of preclinical studies demonstrating that the company’s Oxiplex Gel was effective in reducing perivascular adhesions in artificial disc surgery. The poster presentation is being made at the Spine Arthroplasty Summit 6 (SAS6) of the Spine Arthroplasty Society held in Montreal, …

SAN LUIS OBISPO, California – December 12, 2005 – FzioMed, Inc. announced today that it has submitted its third Pre-Market Approval (PMA) application module to the U.S. Food and Drug Administration for the company’s Oxiplex/SP Adhesion Barrier Gel. Four modules are required to complete FzioMed’s PMA application for approval to market Oxiplex/SP Gel in the …

SAN LUIS OBISPO, California – November 28, 2005 – FzioMed, Inc. announced today the publication of positive results from a U.S. clinical trial of Oxiplex/AP for adhesion prevention in laparoscopic gynecological surgery. The peer-review article “Reduction of Postoperative Adhesions Following Laparoscopic Gynecological Surgery with Oxiplex/AP Gel: A Pilot Study” was published in the November 2005 …

SAN LUIS OBISPO, California – November 15, 2005 – FzioMed, Inc. announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH) to support development of a novel injectable product for acceleration of bone …

SAN LUIS OBISPO, California – November 10, 2005 – FzioMed, Inc. announced today that it has obtained the exclusive, worldwide license to a broad platform of patents and intellectual property covering novel, synthetic peptides from the University of Southern California (USC) for use in the regeneration of bone, cartilage and skeletal tissue. The worldwide license …

SAN LUIS OBISPO, California – October 19, 2005 – FzioMed, Inc. announced today the expansion of its senior management team with the appointment of Ronald J. Ehmsen, ScD as Vice President of Clinical Affairs. Dr. Ehmsen will be responsible for overall planning and direction of the company’s clinical research activities and for ensuring the effective …

SAN LUIS OBISPO, California – September 28, 2005 – FzioMed, Inc. announced today the presentation of preclinical studies demonstrating Oxiplex Gel as an effective drug vehicle, including results with a novel bone growth factor. The poster presentation is being made at the North American Spine Society (NASS) 20 th Annual Meeting held in Philadelphia, PA …

SAN LUIS OBISPO, California – September 14, 2005 – FzioMed, Inc. announces the presentation of clinical results from multi-center studies demonstrating that Oxiplex/AP significantly reduced the formation of postsurgical adhesions in patients undergoing laparoscopic surgery for treatment of endometriosis. The oral presentation is being made at IX World Congress on Endometriosis held in Maastricht, The …

SAN LUIS OBISPO, California – August 11, 2005 – FzioMed, Inc. announced today the issuance of United States patent 6,923,961 which broadens coverage for the company’s proprietary Oxiplex technology in the fields of drug delivery and hemostasis. Oxiplex is a versatile synthetic biomaterial developed by FzioMed for use in a wide variety of surgical specialties. …

SAN LUIS OBISPO, California – July 19, 2005 – FzioMed, Inc. is pleased to announce the appointment of John S. Krelle as President and Chief Operating Officer of the privately held biomaterials company. Ronald F. Haynes, founder of FzioMed, will continue in his role as Chief Executive Officer and Chairman of the Board. As President …

SAN LUIS OBISPO, California – July 6, 2005 – FzioMed, Inc. announced today the presentation of preclinical studies demonstrating Oxiplex Gel as an injectable drug delivery system for a novel, synthetic peptide bone growth factor. The poster presentation is being made at the 12th International Meeting on Advanced Spine Techniques (IMAST) held in Banff, Alberta, …

SAN LUIS OBISPO, California – June 16, 2005 – FzioMed, Inc. announced today that it has signed an agreement appointing Ethicon, Inc., a global medical device company, as the exclusive distributor of FzioMed’s Oxiplex/AP, a bioabsorbable product for use in adhesion prevention in abdominal and pelvic surgeries. Under the agreement, Ethicon will have exclusive rights …

SAN LUIS OBISPO, California - April 11, 2005 - FzioMed, Inc. announced today that it has been awarded a new United States patent covering the company's Oxiplex® technology. Oxiplex is a versatile polymer biomaterial developed by FzioMed for use in a wide variety of surgical specialties. The new patent, US 6,869,938, covers compositions of polyacids …

SAN LUIS OBISPO, California – October 13, 2004 - FzioMed, Inc. announces the presentation of positive clinical results of its Oxiplex/AP Gel, an adhesion barrier for laparoscopic gynecological surgery. The oral presentation will be made at the 13 th Annual Congress of the European Society of Gynaecological Endoscopy being held October 14 – 17, 2004 …

SAN LUIS OBISPO, California - June 30, 2004 - FzioMed, Inc. today announced the presentation of preclinical data showing that Oxiplex/SP Adhesion Barrier Gel for Spine Surgery does not inhibit healing in non-critical bone defects. The poster presentation is being made at the 11th International Meeting on Advanced Spine Techniques (IMAST) held in Bermuda from …

SAN LUIS OBISPO, California - June 11, 2004 - FzioMed, Inc. today announced that it has completed biocompatibility studies of an Oxiplex gel for use in soft tissue augmentation. Oxiplex is a synthetic, bioabsorbable material that can be formulated for use in a wide variety of surgical applications. FzioMed's tissue augmentation program is focused on …

SAN LUIS OBISPO, California - June 9, 2004 - FzioMed, Inc. today announced that the Company completed its United States pilot clinical trial of Oxiplex/AP Gel, an adhesion barrier for laparoscopic gynecological surgery. The randomized, multi-center trial was conducted to determine the safety of Oxiplex/AP Gel for the reduction of postoperative adhesions following laparoscopic gynecological …

SAN LUIS OBISPO, California - May 10, 2004 - FzioMed, Inc. today announced that it will present at the Rodman & Renshaw Techvest Global Healthcare Conference to be held May 12-14, 2004, at Claridge's Hotel in London, UK. Ronald F. Haynes, President and CEO of FzioMed, is scheduled to speak at 2:30 pm BST on …

SAN LUIS OBISPO, California - November 24, 2003 - FzioMed, Inc. will present clinical data of its Oxiplex/AP Gel, Adhesion Barrier for Abdominal/Pelvic Surgery, at the Annual Congress of the European Society of Gynaecological Endoscopy being held November 26 - 29, 2003 in Luxembourg. Richard Berg, PhD., Vice President of Research and Development, will present …

SAN LUIS OBISPO, California - October 16, 2003 - FzioMed, Inc. announced that Ronald F. Haynes, President and CEO of FzioMed, will present at the Rodman & Renshaw Techvest Healthcare Conference on Tuesday, October 21, 2003 at 6:20 pm. The conference will be held at the Long Wharf Marriott Hotel in Boston, MA and will …

SAN LUIS OBISPO, California - August 11, 2003 - FzioMed, Inc. is presenting additional follow-up data from the company's Oxiplex/SP Adhesion Barrier Gel clinical trial this week at the Council of Spine Societies' World Spine II conference in Chicago, Illinois. The results demonstrated that the benefits of using Oxiplex/SP Adhesion Barrier Gel in laminectomy, laminotomy …

SAN LUIS OBISPO, California - July 22, 2003 - FzioMed, Inc. announced today that it has relocated and expanded its corporate headquarters in San Luis Obispo, California.FzioMed's newly constructed facility includes larger areas for clean room manufacturing of the company's Oxiplex® products, expanded research and clinical trial management activities, and administrative offices."FzioMed is growing rapidly …

SAN LUIS OBISPO, California - June 27, 2003 - FzioMed, Inc. announced today the presentation of preclinical data showing the inhibition of post-surgical adhesion reformation using the company's site-specific Oxiplex® gel. The poster presentation was made at the SEGI World Meeting on Minimally Invasive Surgery in Gynecology held in Rome, Italy from June 24 to …

SAN LUIS OBISPO, California - June 11, 2003 - FzioMed, Inc. announced today that it has been awarded United States patent 6,566,345 covering new formulations and delivery methods for the company's Oxiplex® technology. Oxiplex® is a unique polymer technology developed by FzioMed for use in applications such as post-surgical adhesion prevention. The patent covers new …

SAN LUIS OBISPO, Calif. - May. 15, 2003 - FzioMed, Inc. announces that positive clinical study results of Oxiplex/SP Gel were published in the May 2003 issue of Spine (Volume 28, pages 1080-1088). The peer-review article reports the reduction of pain and radiculopathy with the use of Oxiplex/SP Gel after laminectomy, laminotomy and discectomy surgery. The …

SAN LUIS OBISPO, Calif. - Feb. 11, 2003 - FzioMed, Inc. announced today that it has received approval in Europe to expand the label claims for its Oxiplex®/SP Gel for use in spine surgery to include the reduction of pain and radiculopathy.Oxiplex®/SP Gel is a bioabsorbable gel that is applied during spine surgery as a …

SAN LUIS OBISPO, Calif. - Oct. 15, 2002 - FzioMed, Inc., a leading developer of absorbable biosurgery products, presented findings from its pre-clinical research to develop an anti-adhesion product for use in preventing post-surgical adhesions in abdominal/pelvic surgery. The presentation was made at the 58th Annual Meeting of the American Society for Reproductive Medicine held …

FzioMed to Supply Adhesion Prevention Product to Spine Industry Leader SAN LUIS OBISPO, Calif. - Aug. 26, 2002 - FzioMed, Inc., a leading developer of absorbable biosurgery products, announced today it has signed a distribution agreement with Medtronic Sofamor Danek, headquartered in Memphis, Tenn. FzioMed is engaged in the development and manufacture of advanced, absorbable …

SAN LUIS OBISPO, California - July 8, 2002 - FzioMed, Inc., the developer of Oxiplex® technology, announced today it has signed a European distribution agreement with DePuy AcroMed, Inc. FzioMed is engaged in the development and manufacture of advanced, absorbable biosurgery products. DePuy AcroMed, a Johnson & Johnson company, is a spine industry leader focused …

SAN LUIS OBISPO, California - Aug. 30, 2001 - FzioMed, Inc. will exhibit at the Annual International Conference of The International Society of Orthopaedic Surgery and Traumatology (SICOT) to be held August 30 - September 1, 2001 at the Palais des Congres in Paris, France. SICOT is the world orthopaedic organization; a global association of specialized surgeons …

SAN LUIS OBISPO, California - July 2, 2001 - FzioMed, Inc. announced today that it has been awarded the CE Mark certification for its Oxiplex™ adhesion barrier technology for use in spine, abdominal and pelvic surgery. The CE Mark allows FzioMed's Oxiplex™/SP Gel and Oxiplex™ Adhesion Barrier Film products to be marketed and sold throughout …

Medical Industry Today Date: 2/12/2001Companies: FzioMed Inc.Category: Devices The FDA recently approved the multicenter study of Oxiplex/SP, which is applied within the surgical site to reduce post-operative peridural scarring, or post-surgical adhesions. Adhesions are an abnormal, fibrous type of internal scar tissue that forms attachments, often between tissues and organs, tethering organs that normally would …

SAN LUIS OBISPO, California - February 5, 2001 - FzioMed, Inc. announced today that it has initiated a clinical trial of the company's Oxiplex™/SP spine surgery product. The U.S. Food and Drug Administration (FDA) recently approved FzioMed's Investigational Device Exemption (IDE) application to conduct a multi-center clinical pilot study of the new product. Oxiplex™/SP is …

Actions by U.S. Patent Office Extend FzioMed's Coverage for Oxiplex™ Technology in Surgical Adhesion Prevention SAN LUIS OBISPO, California - January 15, 2001 - FzioMed, Inc. announced today that it has received its seventh United States patent for the company's Oxiplex™ technology. The company also received a notice of allowance for an additional patent covering …

Facility Certified to ISO 9001, EN46001 and ISO 13485 Standards SAN LUIS OBISPO, California - December 19, 2000 - FzioMed, Inc., the developer of Oxiplex™ technology, announced today it has received ISO 9001 certification. FzioMed's Oxiplex™ technology is used to produce bioresorbable materials for surgical and medical applications. FzioMed, Inc. has received certification from KEMA …